ARI 3037MO

Drug Profile

ARI 3037MO

Alternative Names: ARI-3037MO

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arisaph Pharmaceuticals
  • Class Antihyperlipidaemics; Small molecules
  • Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dyslipidaemias; Hypertriglyceridaemia; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 14 Jun 2018 No recent reports on development identified - Phase-II for Dyslipidaemias in USA (PO)
  • 14 Jun 2018 No recent reports on development identified - Phase-II for Hypertriglyceridaemia in USA (PO)
  • 14 Jun 2018 No recent reports on development identified - Phase-II for Non-alcoholic fatty liver disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top